SCHEMBL2850181

SCHEMBL2850181

CCC1(c2ccc3cc(C(=O)NC(C)c4cnn(C)c4C)ccc3n2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 1/20 0.54
RAB9A P51151 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
PKM P14618 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPC1 O15118 1/20 0.36
CYP17A1 P05093 1/20 0.35
CCNC P24863 2/20 0.34
CDK8 P49336 2/20 0.34
TAS1R3 Q7RTX0 2/20 0.34
TAS1R1 Q7RTX1 2/20 0.34
CDK2 P24941 1/20 0.34
AKT1 P31749 1/20 0.34
SLC8A1 P32418 1/20 0.33
GAA P10253 1/20 0.33
PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1847132 0.88 BRPF1 (0.52) BRPF1RAB9AKDM4EALDH1A1MAPT
SCHEMBL1839642 0.88 BRPF1 (0.52) BRPF1RAB9AKDM4EALDH1A1MAPT
SCHEMBL1842642 0.78 BRPF1 (0.54) BRPF1RAB9AKDM4EALDH1A1MAPT
SCHEMBL1844278 0.78 BRPF1 (0.54) BRPF1RAB9AKDM4EALDH1A1MAPT
SCHEMBL1842507 0.77 BRPF1 (0.52) BRPF1RAB9AKDM4EALDH1A1MAPT
SCHEMBL1842139 0.77 BRPF1 (0.52) BRPF1RAB9AKDM4EALDH1A1MAPT
SCHEMBL12571642 0.76 BRPF1 (0.51) BRPF1RAB9AKDM4EALDH1A1MAPT
SCHEMBL1838653 0.76 BRPF1 (0.51) BRPF1RAB9AKDM4EALDH1A1MAPT
SCHEMBL1841353 0.76 BRPF1 (0.51) BRPF1RAB9AKDM4EALDH1A1MAPT
SCHEMBL14217731 0.74 BRPF1 (0.56) BRPF1RAB9AKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267769-A1 Substituted Bicyclocarboxyamide Compounds Pfizer, Inc. and Renovis Inc. 2010-10-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267769-A1 Substituted Bicyclocarboxyamide Compounds TRPV1, OPRL1, CNR1 BRPF1 1691/4885RAB9A 2103/4885KDM4E 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.